Abstract:The aging eye appears to be at considerable risk from oxidative stress. A great deal of research indicates that dysfunctional mitochondria are the primary site of reactive oxygen species (ROS). More than 95% of O2 produced during normal metabolism is generated by the electron transport chain in the inner mitochondrial membrane. Mitochondria are also the major target of ROS. Cataract formation, the opacification of the eye lens, is one of the leading causes of human blindness worldwide, accounting for 47.8% of all causes of blindness. Cataracts result from the deposition of aggregated proteins in the eye lens and lens fiber cell plasma membrane damage, which causes clouding of the lens, light scattering, and obstruction of vision. ROS-induced damage in the lens cell may consist of oxidation of proteins, DNA damage, and/or lipid peroxidation, all of which have been implicated in cataractogenesis. This article is an attempt to integrate how mitochondrial ROS are altered in the aging eye along with those protective and repair therapeutic systems believed to regulate ROS levels in ocular tissues and how damage to these systems contributes to age-onset eye disease and cataract formation. Mitochondria-targeted antioxidants might be used to effectively prevent ROS-induced oxidation of lipids and proteins in the inner mitochondrial membrane in vivo. As a result of the combination of weak metal chelating, OH and lipid peroxyl radicals scavenging, reducing activities to liberated fatty acid, and phospholipid hydroperoxides, carnosine and carcinine appear to be physiological antioxidants able to efficiently protect the lipid phase of biologic membranes and aqueous environments and act as the antiapoptotic natural drug compounds The authors developed and patented the new ophthalmic compositions, including N-acetylcarnosine, acting as a prodrug of naturally targeted to mitochondria L-carnosine endowed with pluripotent antioxidant activities combined with mitochondria-targeted rechargeable antioxidant (either MitoVit E, Mito Q, or SkQs) as a potent medicine to treat ocular diseases. Such specificity is explained by the fact that developed compositions might be used to effectively prevent ROS-induced oxidation of lipids and proteins in the inner mitochondrial membrane in vivo and outside mitochondria in the cellular and tissue structures of the lens and eye compartments. Mitochondrial targeting of compounds with universal types of antioxidant activity represents a promising approach for treating a number of ROS-related ocular diseases of the aging eye and can be implicated in the management of cataracts.

Cataract formation and prevention

Research progress on antioxidants and protein aggregation inhibitors in cataract prevention and therapy (Review)

The human lens: An antioxidant-dependent tissue revealed by the role of caffeine

Oxidative Stress and Cataract Formation: Evaluating the Efficacy of Antioxidant Therapies

Oxidative stress and antioxidants in cataract development

Oxidative Stress in Cataract Formation: Is There a Treatment Approach on the Horizon?

“Important Players” in the Development of Age-Related Cataracts (Literature Review)

Current Trends in the Pharmacotherapy of Cataracts

Free Radicals, Antioxidants and Eye Diseases: Evidence from Epidemiological Studies on Cataract and Age-Related Macular Degeneration

Identification of new antioxidant drugs in a human in vitro model of ageing‐associated cataract

Progress on pathogenesis, prevention and treatment of cataract

Research progress on the correlation between cataract occurrence and nutrition

Reactive Oxygen Species and Eye Aging in Cataracts through Biomolecular Mechanisms

Effects of lutein on the prevention and treatment of age-related cataract

Reported evidence of vitamin E protection against cataract and glaucoma

[Protein Post-Translational Modification and Age-Related Cataract].

Epidemiologic Studies of Age-Related Cataract

Oxidative Stress in Genetic Cataract Formation

Vitamin C And Risk Of Age-Related Cataracts: A Systematic Review And Meta-Analysis

Advances in drug therapy and delivery for cataract treatment